JP2004538275A - ヒトインターフェロン−β配合物 - Google Patents
ヒトインターフェロン−β配合物 Download PDFInfo
- Publication number
- JP2004538275A JP2004538275A JP2003511859A JP2003511859A JP2004538275A JP 2004538275 A JP2004538275 A JP 2004538275A JP 2003511859 A JP2003511859 A JP 2003511859A JP 2003511859 A JP2003511859 A JP 2003511859A JP 2004538275 A JP2004538275 A JP 2004538275A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ifn
- buffer
- glycine
- lyophilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 title abstract description 9
- 150000001875 compounds Chemical class 0.000 title 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 143
- 239000004471 Glycine Substances 0.000 claims abstract description 71
- 239000000872 buffer Substances 0.000 claims abstract description 67
- 230000001580 bacterial effect Effects 0.000 claims abstract description 10
- 108090000467 Interferon-beta Proteins 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 102100026720 Interferon beta Human genes 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 169
- 238000003860 storage Methods 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 21
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 7
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims description 4
- 239000008223 sterile water Substances 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 239000002510 pyrogen Substances 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 108010005714 Interferon beta-1b Proteins 0.000 claims 4
- 229960003161 interferon beta-1b Drugs 0.000 claims 4
- 238000009472 formulation Methods 0.000 description 93
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 41
- 229930195725 Mannitol Natural products 0.000 description 41
- 239000000594 mannitol Substances 0.000 description 41
- 235000010355 mannitol Nutrition 0.000 description 41
- 239000000523 sample Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 30
- 229930006000 Sucrose Natural products 0.000 description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 22
- 239000005720 sucrose Substances 0.000 description 22
- 230000035899 viability Effects 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 238000004108 freeze drying Methods 0.000 description 14
- 239000012669 liquid formulation Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 239000008215 water for injection Substances 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 238000004925 denaturation Methods 0.000 description 9
- 230000036425 denaturation Effects 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000011084 recovery Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000002934 lysing effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 239000008366 buffered solution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000003996 Interferon-beta Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229960001388 interferon-beta Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008263 liquid aerosol Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30339501P | 2001-07-09 | 2001-07-09 | |
| PCT/US2002/021464 WO2003006053A1 (en) | 2001-07-09 | 2002-07-09 | HUMAN INTERFERON-β FORMULATIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004538275A true JP2004538275A (ja) | 2004-12-24 |
| JP2004538275A5 JP2004538275A5 (enExample) | 2006-01-05 |
Family
ID=23171889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003511859A Pending JP2004538275A (ja) | 2001-07-09 | 2002-07-09 | ヒトインターフェロン−β配合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20030118548A1 (enExample) |
| JP (1) | JP2004538275A (enExample) |
| AR (1) | AR034749A1 (enExample) |
| PE (1) | PE20030303A1 (enExample) |
| TW (1) | TWI241193B (enExample) |
| UY (1) | UY27373A1 (enExample) |
| WO (1) | WO2003006053A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
| TWI272948B (en) * | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
| AU2004264855A1 (en) * | 2003-07-11 | 2005-02-24 | Schering Aktiengesellschaft | Improved recombinant human interferon-beta-1b polypeptides |
| JPWO2006033453A1 (ja) * | 2004-09-22 | 2008-05-15 | 学校法人順天堂 | インターフェロン作用物質の活性増強剤 |
| US7595040B2 (en) * | 2004-11-10 | 2009-09-29 | Novartis Vaccines And Diagnostics, Inc. | Deamidated interferon-β |
| CA2608764A1 (en) * | 2005-05-19 | 2006-11-23 | Schering Ag | Treatment of disease using an improved regulated expression system |
| US20080076729A1 (en) * | 2005-05-19 | 2008-03-27 | Schering Aktiengesellachaft | Interferon-beta gene therapy using an improved, regulated expression system |
| US20070179113A1 (en) * | 2005-05-19 | 2007-08-02 | Schering Aktiengesellachaft | GM-CSF gene therapy for Crohn's disease using an improved regulated expression system |
| DOP2006000117A (es) * | 2005-05-19 | 2007-11-30 | Schering Ag | Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada |
| RU2008107150A (ru) * | 2005-07-29 | 2009-09-10 | Новартис Аг, (Ch) | Способ и система для сворачивания белка ин витро |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5993093A (ja) * | 1982-10-19 | 1984-05-29 | シ−タス・コ−ポレイション | 変形されたインターロイキン―２及びその製造方法 |
| US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
| JPH10500125A (ja) * | 1994-05-16 | 1998-01-06 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ ベノートスハップ | ＩＦＮ−β液体製剤 |
| WO1998028007A1 (en) * | 1996-12-24 | 1998-07-02 | Biogen, Inc. | Stable liquid interferon formulations |
| JP2004529917A (ja) * | 2001-04-09 | 2004-09-30 | カイロン コーポレイション | インターフェロン−βのＨＳＡ非含有処方物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7404589A (nl) * | 1974-04-03 | 1975-10-07 | Stichting Rega V Z W | Werkwijze voor het stabiliseren van interferon. |
| DE2916711A1 (de) * | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
| US4289689A (en) * | 1980-03-14 | 1981-09-15 | Hoffmann-La Roche Inc. | Preparation of homogeneous human fibroblast interferon |
| DE2943016C2 (de) * | 1979-10-24 | 1984-09-06 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Verfahren zur Reinigung von Interferon |
| JPS5651995A (en) * | 1979-10-05 | 1981-05-09 | Green Cross Corp:The | Preparation of interferon |
| NL7907791A (nl) * | 1979-10-23 | 1981-04-27 | Stichting Rega V Z W | Werkwijze voor het zuiveren van interferon. |
| US4315852A (en) * | 1980-11-26 | 1982-02-16 | Schering Corporation | Extraction of interferon from bacteria |
| JPS5821691A (ja) * | 1981-07-29 | 1983-02-08 | Mochida Pharmaceut Co Ltd | α−及びβ−インタ−フェロンの精製方法 |
| EP0082481B2 (en) * | 1981-12-23 | 1990-09-12 | Schering Corporation | Stabilised alpha-interferon formulations and their preparation |
| US4450103A (en) * | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
| AU1234383A (en) * | 1982-03-17 | 1983-09-22 | Inter-Yeda Ltd. | Interferon stabilised with polyvinyl-pyrrolidone |
| US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
| US5643566A (en) * | 1982-09-23 | 1997-07-01 | Cetus Corporation | Formulation processes for lipophilic proteins |
| US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4485017A (en) * | 1982-12-22 | 1984-11-27 | Cetus Corporation | Isolation of human interferon by immunosorbent and high performance liquid chromatography |
| JPS60243028A (ja) * | 1984-04-28 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | インタ−フエロンの可溶化方法 |
| US4643566A (en) * | 1984-07-20 | 1987-02-17 | Canon Kabushiki Kaisha | Particle analyzing apparatus |
| DE3628468A1 (de) * | 1986-08-21 | 1988-03-03 | Thomae Gmbh Dr K | Neue applikationsformen fuer (alpha)-interferone |
| FR2687843A1 (fr) * | 1992-02-24 | 1993-08-27 | Motorola Semiconducteurs | Transistor bipolaire lateral pnp et procede de fabrication. |
| US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| JP3466765B2 (ja) * | 1994-07-27 | 2003-11-17 | キッコーマン株式会社 | ビオチン化ホタルルシフェラーゼ、ビオチン化ホタルルシフェラーゼ遺伝子、新規な組み換え体ｄｎａ、ビオチン化ホタルルシフェラーゼの製造法及び生物発光分析法 |
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5814485A (en) * | 1995-06-06 | 1998-09-29 | Chiron Corporation | Production of interferon-β (IFN-β) in E. coli |
-
2002
- 2002-07-08 UY UY27373A patent/UY27373A1/es not_active Application Discontinuation
- 2002-07-08 AR ARP020102558A patent/AR034749A1/es unknown
- 2002-07-09 JP JP2003511859A patent/JP2004538275A/ja active Pending
- 2002-07-09 US US10/190,838 patent/US20030118548A1/en not_active Abandoned
- 2002-07-09 PE PE2002000613A patent/PE20030303A1/es not_active Application Discontinuation
- 2002-07-09 WO PCT/US2002/021464 patent/WO2003006053A1/en not_active Ceased
- 2002-07-09 TW TW091115171A patent/TWI241193B/zh not_active IP Right Cessation
-
2005
- 2005-02-24 US US11/063,597 patent/US20050163752A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5993093A (ja) * | 1982-10-19 | 1984-05-29 | シ−タス・コ−ポレイション | 変形されたインターロイキン―２及びその製造方法 |
| US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
| JPH10500125A (ja) * | 1994-05-16 | 1998-01-06 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ ベノートスハップ | ＩＦＮ−β液体製剤 |
| WO1998028007A1 (en) * | 1996-12-24 | 1998-07-02 | Biogen, Inc. | Stable liquid interferon formulations |
| JP2004529917A (ja) * | 2001-04-09 | 2004-09-30 | カイロン コーポレイション | インターフェロン−βのＨＳＡ非含有処方物 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003006053A1 (en) | 2003-01-23 |
| PE20030303A1 (es) | 2003-06-21 |
| AR034749A1 (es) | 2004-03-17 |
| TWI241193B (en) | 2005-10-11 |
| US20030118548A1 (en) | 2003-06-26 |
| UY27373A1 (es) | 2003-02-28 |
| US20050163752A1 (en) | 2005-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100799402B1 (ko) | 안정화된 인터루킨 2 | |
| AU695129B2 (en) | Formulations for IL-12 | |
| KR100401401B1 (ko) | 안정한알파인터페론수용액제형 | |
| EP1409018B1 (en) | Stable lyophilized pharmaceutical formulation the igg antibody daclizumab | |
| US5763394A (en) | Human growth hormone aqueous formulation | |
| US6448225B2 (en) | Human growth hormone aqueous formulation | |
| CA2337745C (en) | Human growth hormone aqueous formulation | |
| US5919443A (en) | Stable lyophilized pharmaceutical preparations of G-CSF | |
| JP2004538275A (ja) | ヒトインターフェロン−β配合物 | |
| EP0641216B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING IL-6 stabilized with a non-reducing sugar | |
| AU2003244470B2 (en) | Immunocytokine-containing lyophilized preparation | |
| EP1641486B1 (en) | Stable, aqueous solution of human erythropoietin, not containing serum albumin | |
| CN101657187B (zh) | 稳定的水性g-csf制剂 | |
| KR900004799B1 (ko) | 안정한 감마 인터페론 제제 및 이의 제조방법 | |
| US20080026046A1 (en) | Stable Aqueous G-Csf Conatining Compositions | |
| JP3479082B2 (ja) | トロンボポイエチン組成物 | |
| EP3524231A2 (en) | Stabilized preparation of interferon beta variant | |
| JP2818834B2 (ja) | ＩＬ−１α安定化医薬製剤 | |
| KR20250071252A (ko) | 저 투여량 il-6 제형 및 이의 사용 방법 | |
| KR19990085129A (ko) | 안정한 α-인터페론 용액 제제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050630 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081111 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081118 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090512 |